Brighthouse Financial, Inc. (BHF), the U.S.-focused life insurance and annuity provider that spun off from MetLife back in 2017, has been a rollercoaster ride for investors. That separation marked a pivotal moment, allowing BHF to operate independently amid a tough industry landscape of rising interest rates, pandemic disruptions, and regulatory scrutiny on annuities. Fast forward to today, with shares closing around their recent levels, the company shows signs of stabilization after years of volatility in earnings and revenue. Drawing from the fundamentals, analyst forecasts, insider moves, and price targets, let’s break down what’s driving this stock and what everyday investors might expect next—balancing the numbers with real-world context so you can see the full picture without getting lost in spreadsheets.
Revenue Rollercoaster and Efficiency Shifts
Revenue tells a story of feast or famine for BHF, swinging wildly due to its sensitivity to interest rates and policy sales in the annuity space. Starting from $3.02 billion in 2016, it peaked at a hefty $8.97 billion in 2018—a whopping 197% jump that reflected strong post-spin-off momentum and favorable market conditions. But then came the dips: down to $6.55 billion in 2019 (-27% YoY), rebounding to $8.50 billion in 2020 (+30% amid COVID-driven demand for financial security products), before cratering to $4.98 billion in 2021 (-41%). The 2022 recovery to $6.87 billion (+38%) was impressive, yet 2023 saw another plunge to $4.12 billion (-40%), followed by a modest 2024 uptick to $4.72 billion (+15%).
Why does this matter? Revenue per share (a key efficiency metric for shareholders) mirrors this, climbing from $25.20 in 2016 to $94.19 in 2022 before settling at $77.19 in 2024. Employee productivity, via revenue per employee, hit over $7.1 million in 2018 but has trended down to $3.37 million in 2024 as headcount stabilized around 1,400-1,500 (a slight -7% drop from 2020 peaks). Analyst predictions paint a brighter future: revenue ballooning to $8.73 billion in 2025 (+85% from 2024), $9.05 billion in 2026 (+4%), and $9.22 billion in 2027 (+2%). This suggests a return to growth, likely fueled by higher rates boosting investment income and annuity sales—correlating nicely with improving EBT margins forecasted at positive territory.
Profitability Swings: From Deep Losses to ROE Rebound
Digging into the bottom line, BHF’s path has been brutal but shows resilience. Net income flipped from a massive -$2.94 billion loss in 2016 (pre-spin-off baggage) to a $870 million profit in 2018 (** turnaround of over $3.8 billion, or impossible % from negative**), only to post losses again in 2019-2020 amid low rates hurting reserves (-$735M and -$1.06B). The real fireworks came in 2021-2022: $1.65 billion (from loss to profit) and a stellar $3.88 billion (+135% YoY), driven by reserve releases and market gains. 2023’s -$1.11 billion loss (-129% reversal) stung, but 2024 clawed back to $393 million profit (+135% swing).
EBT margin captures this volatility—negative through much of the teens, peaking at 68.9% in 2022 (a profitability powerhouse, showing how well revenue converted to pre-tax earnings during good times), then recovering to 8.9% in 2024. ROE, crucial for gauging shareholder returns, echoed this: from -20% lows to 34.6% in 2022 (elite territory for insurers), dipping to -22.9% in 2023, and rebounding to 5.7% in 2024. Forecasts? Net income at $459 million in 2025 (+17%), jumping to $1.01 billion in 2026 (+119%) and $1.09 billion in 2027 (+8%), implying ROE around 11% in 2025. This ties to shares outstanding shrinking from 120 million in 2016 to 61 million in 2024 (-49%), boosting per-share metrics like EPS from -$24.54 (2016) to $4.64 (2024), with forecasts hitting $17.38 (2026, +275% from 2024).
Book value per share (BVPS), a safety net for insurers, grew from $121 in 2016 to $193 in 2021 before halving to $76 by 2023 amid losses—now at $82 in 2024 (+8%), though forecasts oddly dip to $63 in 2025 before $84 in 2026. PB ratios hover low (0.59x in 2024), suggesting undervaluation if book quality holds.
Cash Flow Concerns Amid Debt Stability
Cash flows paint a cautionary tale. Operating cash flow per share peaked at $31 in 2016 but eroded to -$4.74 in 2024, with free cash flow mirroring negatives in recent years (e.g., -$290 million total FCF in 2024). No capex drag helps, but working capital swings— from -$13.5 billion (2016) to -$5.3 billion (2024, +61% improvement)—signal liquidity strains from policy liabilities. Total debt is steady at ~$3.16 billion (2022-2024), with net debt turning negative (cash-rich) lately, a positive for balance sheet health. ROIC at 8.4% in 2024 (up from negatives) shows capital efficiency improving, correlating with profitability rebounds.
Stock Price Journey: Volatility Matching Fundamentals
BHF’s stock price has danced to these fundamentals. From 2017’s range of $52.75-$75 (post-spin-off hype), it plunged to $12-$48 in 2020 (COVID lows, aligning with losses and rate fears), recovered to $35-$57 in 2021 and $38-$62 in 2022 (profit boom), but moderated to $39-$61 in 2023 amid the loss. 2024’s $40-$55 range reflects the profit return but muted enthusiasm. Recent close sits steady, with historical highs (75) about 17% above current, lows (12) 81% below—typical for a cyclical insurer. PE expanded from dirt-cheap (near 0) to 9.3x in 2024, forecasted to compress to 3.7x by 2026 on EPS growth, hinting at value if earnings deliver. PS and PB ratios stayed low (under 1x), often below 0.7x, screaming “bargain” relative to revenue stability versus peaks.
This price action correlates tightly with earnings volatility: profits drove 2021-22 rallies, losses capped 2023 gains. Compared to book value erosion, shares traded at premiums during good times (PB 0.67x in 2022) but discounts lately—opportunity if turnaround sticks.
Insider Activity: All Sells, No Buys
Insider transactions over the past year (through early 2026) are a yellow flag: zero buys, but several sells totaling over $2.8 million in value. Notably, the EVP CHRO and EVP Chief Marketing & Distribution Officer unloaded 3,000 and 8,400 shares each in March and June 2025 at averages around $59-$60/share, while the President/CEO sold 25,000 shares in May 2025 near $59. These aren’t panic dumps (routine for execs exercising options), but the absence of buys amid forecasted growth raises eyebrows—insiders aren’t loading up, potentially signaling caution on near-term execution despite improving metrics.
Analyst Outlook and Price Targets
Analysts are cautiously optimistic, baking in revenue surges and EPS explosions for 2025-2027, driven by rate normalization post-Fed hikes (a tailwind since 2022) and annuity demand. EBT at $1.34 billion in 2025 (from $422M in 2024, +218%) supports this. Price targets relative to the recent close imply modest upside: low end about 14% below (defensive view), average around 6% above (consensus bet on recovery), high 10% over (bullish on forecasts). EV/Sales dips to 0.4x by 2026, cheap for growth.
Wrapping Up: Value Play with Risks
BHF’s story is one of extremes—massive losses tied to spin-off cleanup and rate cycles, offset by blowout profits when stars align. Fundamentals now point to a pivot: shrinking shares amplifying EPS, steady debt, and forecasts screaming growth. Yet cash flow woes and insider sells temper enthusiasm; watch for sustained positives like ROE above 10% and FCF flips. For retail investors, it’s a speculative value bet—trading at depressed multiples with 6% average upside potential. If rates hold and annuities boom (post-2022 trends), 2026 could shine; otherwise, volatility persists. Pair this with diversification, and it might fit a patient portfolio. Keep an eye on Q1 2026 earnings for confirmation.